1 Min Read
March 30 (Reuters) - Akari Therapeutics Plc
* Akari Therapeutics announces FDA fast track designation for Coversin
* Akari Therapeutics Plc says is evaluating coversin in two Phase 2 clinical trials Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.